Authors:

Yuien-Chun, PhD

Professor, Fooyin University, No.151, Chin-Hsueh Rd, Daliao District, Kaohsiung City. China

Abstract:

Background The aim of the study was to assess the effectivity and safety of tofacitinib and its impact on quality of life in patients with moderate-to-severe colitis. Methods we have a tendency to conducted a scientific review and meta-analysis of randomised controlled trials scrutiny tofacitinib with placebo or any active comparator. we have a tendency to searched phone system, Embase, the Cochrane Library and grey literature for articles revealed up to could 2017. we have a tendency to synthesized knowledge employing a fixed-effect model. we have a tendency to conducted subgroup analysis supported previous exposure to anti-tumor gangrene issue (TNF). we have a tendency to summarized the strength of proof exploitation the Grading of Recommendations Assessment, Development and analysis (GRADE) approach. Results we have a tendency to enclosed 3 trials with 1220 participants. Compared with placebo, tofacitinib was effective in causation clinical remission (odds magnitude relation [OR] three.84, ninety fifth confidence interval [CI] a pair of.29-6.44, I2: 41%, GRADE: moderate), clinical response (OR a pair of.95, 95%CI 2.21-3.95, I2: 0%, GRADE: high), membrane healing (OR a pair of.70, 95%CI 1.81-4.03, I2: 0%, GRADE: high). Tofacitinib was effective in each anti-TNF-naïve and -experienced patients. Tofacitinib had a good result on quality of life. there have been no important variations within the safety profile in terms of the incidence of any or serious adverse events compared to placebo. the chance for infections was redoubled (OR one.51, 95%CI 1.05-2.19, I2: 0%, GRADE: moderate), however the incidence of significant infections didn’t dissent between tofacitinib and placebo. Conclusion In patients with moderate-to-severe colitis, short treatment with tofacitinib is effective for induction of remission and improvement of quality of life.

Keywords:
Tofacitinib, ulcerative colitis, meta-analysis.

Citation:

Yuien-Chun, PhD. Tofacitinib for ulcerative colitis remission: a comprehensive review and meta-analysis Japanese Journal of Gastroenterology 2022.